Additionally, the long-term use of GLP-1 agonists has been associated with a reduced incidence of hospitalization for ischemic stroke in Asian patients with type 2 diabetes. On the other hand, the efficacy of SGLT2 inhibitors in stroke prevention is still uncertain, although ...
图1 GLP-1受体激动剂和SGLT2抑制剂在心血管实践中的应用 注:*对于卒中风险较高或有TIA/卒中史的患者,可考虑将GLP-1受体激动剂初步整合到管理计划中,之后再根据心衰/肾脏状态的变化或者为进一步降低A1c来整合SGLT2抑制剂 患者筛查 ...
16. Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis o...
来源:Bao Y, Hu Y, Shi M, Zhao Z. SGLT2 inhibitors reduce epicardial adipose tissue more than GLP-1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta-analysis. Diabetes Obes Metab. 2024 Dec 6. 转载: 请标明“中...
[27] Luli, Alex, et al. "Barriers to Obtaining GLP-1 Receptor Agonists and SGLT2 Inhibitors in a Free Clinic Population With Type 2 Diabetes and Cardiovascular Disease." Journal of Contemporary Pharmacy Practice 70.1 (2023): 9-13.[28] Mahtta, Dhruv, et al. "Utilization rates of SGLT2...
1879 Send Orders for Reprints to reprints@benthamscience.ae Current Pharmaceutical Design, 2018, 24, 1879-1886 REVIEW ARTICLE Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints 1,2 1 1 1 Michael Doumas , Κonstantinos Imprialos , ...
2024年7月8日,乔治全球健康研究中心的研究人员在《柳叶刀》子刊" The Lancet Diabetes & Endocrinology "上发表了一篇题为" Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists:a SMART-C collaborative meta-analysis of randomised controlled trials "的论文。
SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review https://pubmed.ncbi.nlm.nih.gov/33368612/...
Compared with GLP-1 agonists, SGLT2 inhibitors were linked with similar cardiovascular outcomes but less heart failure, treatment discontinuation, healthcare use, and cost in a new study.
在这项队列研究中,与单独使用任何一类药物相比,GLP-1受体激动剂-SGLT-2抑制剂联合使用发生主要不良心血管事件和严重肾脏事件的风险较低。 知识来源 [1] SIMMS-WILLIAMS N, TREVES N, YIN H, et al. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotranspor...